Vmn2r27 Inhibitors
Vmn2r27 can affect the function of this protein through various mechanisms of action, each related to the inhibition of specific signaling pathways within cells. For instance, Olmutinib and Gefitinib target the epidermal growth factor receptor (EGFR) tyrosine kinase, which plays a significant role in many signaling cascades, including those that can intersect with G-protein coupled receptor (GPCR) activity. By inhibiting EGFR, these chemicals can reduce the cross-talk between receptor tyrosine kinase signaling and GPCR-mediated pathways, thereby inhibiting the function of Vmn2r27. Similarly, Erlotinib also selectively inhibits EGFR, potentially leading to a decrease in the functional signaling of Vmn2r27. Lapatinib, which inhibits both HER2 and EGFR, can disrupt the interactions between these kinases' pathways and GPCR signaling, thus affecting Vmn2r27 activity.
Dasatinib and Bosutinib, which are Src family kinase inhibitors, can interfere with the signaling mechanisms of G-protein coupled receptors. By inhibiting Src kinases, these chemicals can attenuate the G-protein-mediated signaling that Vmn2r27 relies on for its activity. Vandetanib works in a similar fashion by targeting multiple tyrosine kinases, including VEGFR, EGFR, and RET, which can disrupt the signaling pathways that influence GPCR activity. Sorafenib, as a RAF inhibitor that also targets VEGFR and PDGFR, may reduce the efficacy of downstream signaling required for Vmn2r27 function. Nintedanib and Sunitinib, inhibitors of angiogenesis-related tyrosine kinases like VEGFR, PDGFR, and FGFR, can alter the cellular signaling environment and indirectly inhibit Vmn2r27 by changing the activity levels of related GPCR pathways. Axitinib's selective inhibition of VEGFRs further supports the notion that modulating these receptors can influence the cellular context and signaling dynamics affecting Vmn2r27 function. These chemicals collectively provide a comprehensive approach to modulating the intricate web of signaling pathways that can regulate the activity of Vmn2r27.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a Src family kinase inhibitor. Src family kinases are known to interact with and modulate GPCR signaling. By inhibiting Src kinases, Dasatinib could attenuate the G-protein-mediated signaling cascades that Vmn2r27 depends upon for its function. | ||||||
BIBF1120 | 656247-17-5 | sc-364433 sc-364433A | 5 mg 10 mg | $184.00 $321.00 | 2 | |
Nintedanib is a tyrosine kinase inhibitor that targets receptors like VEGFR, PDGFR, and FGFR, which are involved in angiogenesis and cell survival pathways. These pathways can influence GPCR function, and thus, Nintedanib may indirectly inhibit Vmn2r27 by altering cellular contexts in which Vmn2r27 operates. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib is a receptor tyrosine kinase inhibitor, affecting receptors like VEGFR and PDGFR. By modulating these receptors' activity, sunitinib may alter the cellular signaling environment that influences Vmn2r27 signaling pathways, leading to functional inhibition. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib targets the EGFR tyrosine kinase, which can regulate GPCR function through downstream signaling pathways. The inhibition of EGFR by Gefitinib can disrupt potential EGFR-mediated modulation of Vmn2r27 function. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib is an inhibitor of HER2 and EGFR, both of which are involved in signaling pathways that can cross-talk with GPCR-mediated signaling. By inhibiting these kinases, Lapatinib might reduce the signaling interactions that contribute to Vmn2r27's function. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $130.00 $182.00 | 2 | |
Pazopanib is a multi-target tyrosine kinase inhibitor, with activity against VEGFR, PDGFR, and c-Kit. The inhibition of these kinases can alter the signaling milieu in which Vmn2r27 operates, thereby inhibiting its functional signaling indirectly. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a RAF inhibitor but also inhibits VEGFR and PDGFR kinases. These pathways, when inhibited by Sorafenib, may reduce the potential for GPCR like Vmn2r27 to function effectively due to diminished downstream signaling. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Vandetanib inhibits VEGFR, EGFR, and RET tyrosine kinases. By targeting these kinases, Vandetanib can disrupt signaling pathways that influence the functional state of GPCRs, potentially leading to a decrease in Vmn2r27 activity. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib selectively inhibits EGFR tyrosine kinase. GPCRs, including Vmn2r27, may have their function modulated by EGFR-mediated pathways, and inhibition by Erlotinib can therefore indirectly inhibit Vmn2r27 signaling. | ||||||